[go: up one dir, main page]

WO2000050089A3 - Regulation of the stability of recombinant proteins and antiboodies - Google Patents

Regulation of the stability of recombinant proteins and antiboodies Download PDF

Info

Publication number
WO2000050089A3
WO2000050089A3 PCT/US2000/004749 US0004749W WO0050089A3 WO 2000050089 A3 WO2000050089 A3 WO 2000050089A3 US 0004749 W US0004749 W US 0004749W WO 0050089 A3 WO0050089 A3 WO 0050089A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
antibody
antiboodies
regulation
stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/004749
Other languages
French (fr)
Other versions
WO2000050089A2 (en
Inventor
Daniel G Chain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mindset Biopharmaceuticals (USA)
Original Assignee
Mindset Biopharmaceuticals (USA)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindset Biopharmaceuticals (USA) filed Critical Mindset Biopharmaceuticals (USA)
Priority to AU36048/00A priority Critical patent/AU3604800A/en
Publication of WO2000050089A2 publication Critical patent/WO2000050089A2/en
Publication of WO2000050089A3 publication Critical patent/WO2000050089A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An antibody to a drug of interest is caused to be expressed in a target cell of interest by genetic therapy. This antibody is expressed along with a promoter and modulator for the antibody. The drug is administered to the patient, where it binds to the antibody for the drug until a critical concentration of drug is reached at the target site. Once this critical concentration of drug is achieved, the antibody is released from the drug/antibody conjugate, and the drug is available at the target site in concentrations sufficient to treat the condition for which the drug is administered. In order to ensure that the antibodies are degraded at the proper time, the antibodies are designed to have built-in signals for degradation.
PCT/US2000/004749 1999-02-26 2000-02-25 Regulation of the stability of recombinant proteins and antiboodies Ceased WO2000050089A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36048/00A AU3604800A (en) 1999-02-26 2000-02-25 Method for regulating the stability of recombinant proteins, and antibodies and products useful therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12210399P 1999-02-26 1999-02-26
US60/122,103 1999-02-26

Publications (2)

Publication Number Publication Date
WO2000050089A2 WO2000050089A2 (en) 2000-08-31
WO2000050089A3 true WO2000050089A3 (en) 2001-03-29

Family

ID=22400626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/004749 Ceased WO2000050089A2 (en) 1999-02-26 2000-02-25 Regulation of the stability of recombinant proteins and antiboodies

Country Status (2)

Country Link
AU (1) AU3604800A (en)
WO (1) WO2000050089A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235864A1 (en) * 2002-06-05 2003-12-25 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
EP1988920A1 (en) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000356A1 (en) * 1989-06-30 1991-01-10 Massachusetts Institute Of Technology Inhibition of the n-end rule pathway in living cells
FR2706486A1 (en) * 1993-06-16 1994-12-23 Rhone Poulenc Rorer Sa Nucleic sequences, vectors containing them, pharmaceutical compositions and therapeutic uses.
WO1996026733A1 (en) * 1995-03-01 1996-09-06 Alexander Varshavsky Codominance-mediated toxins
US5705387A (en) * 1994-02-04 1998-01-06 California Institute Of Technology Heat-inducible N-degron module
WO1998003538A2 (en) * 1995-10-27 1998-01-29 California Institute Of Technology Signal-regulated, cleavage-mediated toxins
US5763212A (en) * 1994-02-04 1998-06-09 California Institute Of Technology Inhibiting degradation of a degron-bearing protein
US5851829A (en) * 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
WO1999014353A2 (en) * 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
WO2000042185A1 (en) * 1999-01-11 2000-07-20 Mindset Biopharmaceuticals (Usa), Inc. Methods for regulating the stability of recombinant proteins and products useful therein

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000356A1 (en) * 1989-06-30 1991-01-10 Massachusetts Institute Of Technology Inhibition of the n-end rule pathway in living cells
FR2706486A1 (en) * 1993-06-16 1994-12-23 Rhone Poulenc Rorer Sa Nucleic sequences, vectors containing them, pharmaceutical compositions and therapeutic uses.
US5851829A (en) * 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
US5705387A (en) * 1994-02-04 1998-01-06 California Institute Of Technology Heat-inducible N-degron module
US5763212A (en) * 1994-02-04 1998-06-09 California Institute Of Technology Inhibiting degradation of a degron-bearing protein
WO1996026733A1 (en) * 1995-03-01 1996-09-06 Alexander Varshavsky Codominance-mediated toxins
WO1998003538A2 (en) * 1995-10-27 1998-01-29 California Institute Of Technology Signal-regulated, cleavage-mediated toxins
WO1999014353A2 (en) * 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
WO2000042185A1 (en) * 1999-01-11 2000-07-20 Mindset Biopharmaceuticals (Usa), Inc. Methods for regulating the stability of recombinant proteins and products useful therein

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A VARSHAVSKY: "The N-end rule: Functions, mysteries, uses", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 93, October 1996 (1996-10-01), pages 12142 - 12149, XP002138160, ISSN: 0027-8424 *
BALTHASAR J P ET AL: "INVERSE TARGETING OF PERITONEAL TUMORS: SELECTIVE ALTERATION OF THEANTIBODIES AND ANTIBODY FRAGMENTS. DISPOSITION OF METHOTREXATE THROUGH THE USE OF ANTI-METHOTREXATE", JOURNAL OF PHARMACEUTICAL SCIENCES,US,AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, vol. 85, no. 10, 1 October 1996 (1996-10-01), pages 1035 - 1043, XP000626797, ISSN: 0022-3549 *
DOHMEN R JURGEN ET AL: "Heat-inducible degron: A method for constructing temperature-sensitive mutants", SCIENCE,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,US, vol. 263, no. 5151, 1994, pages 1273 - 1276, XP002142706, ISSN: 0036-8075 *
LEVY, FREDERIC ET AL: "Analysis of a conditional degradation signal in yeast and mammalian cells", EUR. J. BIOCHEM., VOL. 259, NO. 1/2, PAGE(S) 244-252, January 1999 (1999-01-01), XP000971525 *
NAVARRO-TEULON I ET AL: "Expression in Escherichia coli of soluble and M13 phage-displayed forms of a single-chain antibody fragment specific for digoxin: assessment in a novel drug immunoassay", IMMUNOTECHNOLOGY,NL,ELSEVIER SCIENCE PUBLISHERS BV, vol. 1, no. 1, 1 May 1995 (1995-05-01), pages 41 - 52, XP004052683, ISSN: 1380-2933 *
ROBERTS C J ET AL: "Development of an ELISA using a universal method of enzyme-labelling drug-specific antibodies - Part I: Detection of dexamethasone in equine urine", JOURNAL OF IMMUNOLOGICAL METHODS,NL,ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, vol. 181, no. 2, 26 April 1995 (1995-04-26), pages 157 - 166, XP004021203, ISSN: 0022-1759 *
VARSHAVSKY A ET AL: "THE N-END RULE OF SELECTIVE PROTEIN TURNOVER - MECHANISTIC ASPECTS AND FUNCTIONAL IMPLICATIONS", 1988, M. RECHSTEINER (ED.): "UBIQUITIN", PLENUM PRESS CO., LONDON, GB, PAGE(S) 287-324,, ISBN: 0-306-42850-4, XP000971521 *
VARSHAVSKY A: "CODOMINANCE AND TOXINS: A PATH TO DRUGS OF NEARLY UNLIMITED SELECTIVITY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 92, April 1995 (1995-04-01), pages 3663 - 3667, XP000929682, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU3604800A (en) 2000-09-14
WO2000050089A2 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
Wang et al. Effect of the P-glycoprotein inhibitor, cyclosporine A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats
WO2007097934A3 (en) Methods and compositions for using erythrocytes as carriers for delivery of drugs
Perini et al. Interferon-beta (INF-b) antibodies in interferon-b1a-and interferon-b1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-b immunogenicity in vivo.
Tanaka et al. Regulation of the PepT1 peptide transporter in the rat small intestine in response to 5-fluorouracil–induced injury
EP2164866B1 (en) Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
Öhrvik et al. Orchestration of dynamic copper navigation–new and missing pieces
IL115517A0 (en) Biologically active proteins
WO2007113648A3 (en) Ctla4 antibody combination therapy
SE8902638D0 (en) STABILIZED PROTEIN OR PEPTIDE CONJUGATES
WO1998022136A3 (en) Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies
WO2005047331A3 (en) Antibodies that bind interleukin-4 receptor
WO2004066932A3 (en) Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
NO20025253L (en) Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2005000895A3 (en) Vegf traps and therapeutic uses thereof
WO2008047241A3 (en) Modified corticotropin releasing factor peptides and uses thereof
ATE363533T1 (en) OSTEOPROTEGERIN BINDING PROTEINS AND RECEPTORS
WO2005117952A3 (en) Treatment methods utilizing albumin-binding proteins as targets
WO2002015920A3 (en) Treatment of hyperproliferative diseases
Nittoli et al. Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids
WO2010014225A3 (en) Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
Braun et al. Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate
Mitch et al. Mechanisms activating proteolysis to cause muscle atrophy in catabolic conditions
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
WO2003063780A3 (en) Therapeutic composition for treatment of cancer by arginine depletion
WO1997048804A3 (en) Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase